Breast Cancer Res Treat 173 (2): 247-254, 2019.[PUBMED Abstract] Loibl S, Jassem J, Sonnenblick A, et al.: Adjuvant Pertuzumab and Trastuzumab in Early Human Epidermal Growth Factor Receptor 2-Positive Breast Cancer in the APHINITY Trial: Third Interim Overall Survival Analysis With Efficacy Update.
J Clin Oncol 42 (31): 3643-3651, 2024.[PUBMED Abstract] von Minckwitz G, Huang CS, Mano MS, et al.: Trastuzumab Emtansine for Residual Invasive HER2-Positive Breast Cancer.
N Engl J Med 380 (7): 617-628, 2019.[PUBMED Abstract] Chan A, Delaloge S, Holmes FA, et al.: Neratinib after trastuzumab-based adjuvant therapy in patients with HER2-positive breast cancer (ExteNET): a multicentre, randomised, double-blind, placebo-controlled, phase 3 trial.